Live Satellite Symposium on “B-Cell Malignancies” with CLLAN faculty representation
17 October 2022 – Live Satellite Symposium: Solving the Puzzles for B-Cell Malignancies – Navigating the Place of BTK Inhibitors Today and Tomorrow
12:30 pm – 2:00 pm ET
18:30 – 20:00 CET
CLLAN and Medscape are inviting to an interactive discussion on the role of BTK inhibitors in treating B-cell malignancies – how BTK inhibitors fit into the treatment landscape and the clinical evidence supporting their use. CLLAN´s chair, Nick York, is sitting in the panel of experts and will be representing the patient voice.
Description:
The treatment landscape of B-cell malignancies continues to evolve, with new and novel drugs being investigated and added to the armamentarium. Since their introduction, Bruton tyrosine kinase (BTK) inhibitors have dramatically changed the treatment of B-cell malignancies, emerging as one of the backbones of treatment. The high anti-lymphoma activity of BTK inhibitors has led to approvals to treat chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).
Join our multidisciplinary panel of experts, including hematologists, a specialist nurse, and a patient advocate, as they guide us in an interactive discussion on the role of BTK inhibitors in treating B-cell malignancies – how BTK inhibitors fit into the treatment landscape and the clinical evidence supporting their use. The panel will also explore patient perspectives in the management of their disease using BTK inhibitors, with emphasis on the needs of the patient, and the importance of meeting their treatment goals.
Enhance Your Virtual Experience With Backstage Pass!
Join our 30-minute post-symposium breakout session connecting the program speakers and audience in the virtual environment. Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.
*Video Encouraged*
Moderator:
Christian Buske, MD
Director
Institute of Experimental Cancer Research
University Hospital Ulm
Ulm, Germany
Panelists:
Helen Knight
CLL Clinical Nurse Specialist
The Russell Centre for Clinical Haematology
Nottingham University Hospitals
Nottingham, United Kingdom
Alessandra Tedeschi, MD
Medical Director
Hematology Department
Niguarda Cancer Center
Milan, Italy
Steven Treon, MD, PhD
Professor
Harvard Medical School
Director
Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Nick York
Chair
CLL Advocates Network
Leukemia Patient Advocates Foundation
Bern, Switzerland
Agenda:
MONDAY, OCTOBER 17, 2022
12:30 pm – 2:00 pm et
18:30 – 20:00 cet
Welcome and Introductions
Christian Buske, MD
BTK Inhibitors and B-Cell Malignancies: A Patient View
Nick York
Helen Knight
The Puzzle of CLL: Integrating BTK Inhibitors Across the Disease Continuum
Alessandra Tedeschi, MD
The Puzzle of WM: Genome Profiling Clues to Inform Treatment Decisions With BTK inhibitors
Steven Treon, MD, PhD
The Puzzle of BTK inhibitors and Other Indolent NHLs: Extending Outcomes in Relapsed/Refractory Disease
Christian Buske, MD
The Puzzle of MCL: The Evolving Role of BTK inhibitors
Christian Buske, MD
Conclusion
Christian Buske, MD
Adjourn
2:00 pm – 2:30 pm
Backstage Pass
TARGET AUDIENCE
This activity is intended for an international audience of non-US hematologists/oncologists, pathologists, cardiologists and other healthcare providers involved in the care of patients with B-cell malignancies.
GOAL STATEMENT
The goal of this activity is that learners will be better able to use BTK inhibitors for the individual patient with B-cell malignancies.
LEARNING OBJECTIVES
Upon completion of this activity, participants will:
Have increased knowledge regarding the
– Latest clinical data with BTK inhibitors for B-cell malignancies
– Factors informing treatment decisions with BTK inhibitors for B-cell malignancies
Have greater competence related to
– Using BTK inhibitors to manage patients with B-cell malignancies
Demonstrate greater confidence in their ability to
– Integrate the latest data with BTK inhibitors into the management of patients with B-cell malignancies